4.4 Review

A ride through the epigenetic landscape: aging reversal by reprogramming

期刊

GEROSCIENCE
卷 43, 期 2, 页码 463-485

出版社

SPRINGER
DOI: 10.1007/s11357-021-00358-6

关键词

Epigenetics; Aging; Reprogramming; Rejuvenation

资金

  1. EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine [EP/L015838/1]
  2. AstraZeneca
  3. Diamond Light Source
  4. Defence Science and Technology Laboratory
  5. Evotec
  6. GlaxoSmithKline
  7. Janssen
  8. Novartis
  9. Pfizer
  10. Syngenta
  11. Takeda
  12. UCB
  13. Vertex

向作者/读者索取更多资源

This review explores the interplay between epigenetics and aging, with a focus on the potential of epigenetic reprogramming for age reversal. While in vivo partial reprogramming holds promise as a therapy, there are several limitations that need to be addressed. Reprogramming for rejuvenation is a young but rapidly expanding subfield in the biology of aging.
Aging has become one of the fastest-growing research topics in biology. However, exactly how the aging process occurs remains unknown. Epigenetics plays a significant role, and several epigenetic interventions can modulate lifespan. This review will explore the interplay between epigenetics and aging, and how epigenetic reprogramming can be harnessed for age reversal. In vivo partial reprogramming holds great promise as a possible therapy, but several limitations remain. Rejuvenation by reprogramming is a young but rapidly expanding subfield in the biology of aging.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据